CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...
Read MoreCatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...
Read MoreCatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15...
Read MoreCatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...
Read MoreCatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...
Read MoreCatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...
Read MoreCatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...
Read MoreCatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...
Read MoreCatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...
Read MoreCatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...
Read More